Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GOSS NASDAQ:NVCT NASDAQ:PROK NASDAQ:TYRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGOSSGossamer Bio$3.46$2.08$0.66▼$3.60$786.74M1.954.08 million shs4.24 million shsNVCTNuvectis Pharma$6.16-5.4%$7.01$4.44▼$11.80$156.82M-0.2762,679 shs76,495 shsPROKProKidney$2.48-16.8%$2.79$0.46▼$7.13$876.96M1.742.01 million shs8.25 million shsTYRATyra Biosciences$12.52+0.4%$11.19$6.42▼$29.60$667.28M1.1233,604 shs196,339 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGOSSGossamer Bio0.00%+17.69%+76.53%+179.03%+288.72%NVCTNuvectis Pharma0.00%-7.78%-4.20%-26.75%-4.35%PROKProKidney0.00%+10.22%+2.48%+195.84%+3.33%TYRATyra Biosciences0.00%-1.03%+17.01%+20.04%-38.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGOSSGossamer Bio$3.46$2.08$0.66▼$3.60$786.74M1.954.08 million shs4.24 million shsNVCTNuvectis Pharma$6.16-5.4%$7.01$4.44▼$11.80$156.82M-0.2762,679 shs76,495 shsPROKProKidney$2.48-16.8%$2.79$0.46▼$7.13$876.96M1.742.01 million shs8.25 million shsTYRATyra Biosciences$12.52+0.4%$11.19$6.42▼$29.60$667.28M1.1233,604 shs196,339 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGOSSGossamer Bio0.00%+17.69%+76.53%+179.03%+288.72%NVCTNuvectis Pharma0.00%-7.78%-4.20%-26.75%-4.35%PROKProKidney0.00%+10.22%+2.48%+195.84%+3.33%TYRATyra Biosciences0.00%-1.03%+17.01%+20.04%-38.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGOSSGossamer Bio 3.00Buy$8.50145.66% UpsideNVCTNuvectis Pharma 3.00Buy$15.33148.92% UpsidePROKProKidney 2.33Hold$6.25152.02% UpsideTYRATyra Biosciences 3.14Buy$31.86154.45% UpsideCurrent Analyst Ratings BreakdownLatest NVCT, TYRA, GOSS, and PROK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025GOSSGossamer BioCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight9/10/2025TYRATyra BiosciencesOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$36.009/2/2025TYRATyra BiosciencesRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$35.008/22/2025TYRATyra BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.008/18/2025PROKProKidneyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/6/2025GOSSGossamer BioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$4.00 ➝ $5.008/4/2025NVCTNuvectis PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$15.00 ➝ $10.007/15/2025PROKProKidneyUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$4.00 ➝ $8.007/14/2025GOSSGossamer BioScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSector Outperform$11.007/14/2025PROKProKidneyGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.00 ➝ $7.007/9/2025PROKProKidneyCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.00 ➝ $9.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGOSSGossamer Bio$40.24M19.55N/AN/A$0.13 per share26.62NVCTNuvectis PharmaN/AN/AN/AN/A$0.50 per shareN/APROKProKidney$80K9,122.68N/AN/A($3.41) per share-0.73TYRATyra BiosciencesN/AN/AN/AN/A$6.78 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGOSSGossamer Bio-$56.53M-$0.62N/AN/AN/A-344.81%-1,774.72%-46.73%11/6/2025 (Estimated)NVCTNuvectis Pharma-$19M-$1.17N/AN/AN/AN/A-150.81%-94.84%11/4/2025 (Estimated)PROKProKidney-$61.19M-$0.57N/AN/AN/AN/AN/A-17.11%11/11/2025 (Estimated)TYRATyra Biosciences-$86.48M-$1.78N/AN/AN/AN/A-31.22%-29.49%11/6/2025 (Estimated)Latest NVCT, TYRA, GOSS, and PROK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025TYRATyra Biosciences-$0.53-$0.47+$0.06-$0.47N/AN/A8/12/2025Q2 2025PROKProKidney-$0.14-$0.13+$0.01-$0.13N/A$0.22 million8/5/2025Q2 2025GOSSGossamer Bio-$0.18-$0.17+$0.01-$0.17$4.12 million$11.49 million8/5/2025Q2 2025NVCTNuvectis Pharma-$0.25-$0.30-$0.05-$0.30N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGOSSGossamer BioN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ATYRATyra BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGOSSGossamer Bio6.704.404.40NVCTNuvectis PharmaN/A2.662.66PROKProKidneyN/A11.4811.48TYRATyra BiosciencesN/A21.9421.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGOSSGossamer Bio81.23%NVCTNuvectis Pharma96.77%PROKProKidney51.59%TYRATyra Biosciences84.14%Insider OwnershipCompanyInsider OwnershipGOSSGossamer Bio6.70%NVCTNuvectis Pharma30.52%PROKProKidney41.49%TYRATyra Biosciences15.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGOSSGossamer Bio180227.38 million212.15 millionOptionableNVCTNuvectis Pharma825.46 million17.69 millionNot OptionablePROKProKidney3294.28 million172.18 millionOptionableTYRATyra Biosciences2053.30 million45.20 millionOptionableNVCT, TYRA, GOSS, and PROK HeadlinesRecent News About These CompaniesWall Street Zen Upgrades Tyra Biosciences (NASDAQ:TYRA) to HoldSeptember 14 at 3:47 AM | americanbankingnews.comTyra Biosciences, Inc. $TYRA Shares Acquired by Jacobs Levy Equity Management Inc.September 12 at 3:55 AM | marketbeat.comTyra Biosciences price target raised to $36 from $30 at OppenheimerSeptember 10, 2025 | msn.comPolar Asset Management Partners Inc. Has $1.31 Million Stock Holdings in Tyra Biosciences, Inc. $TYRASeptember 9, 2025 | marketbeat.comNMIBC Pipeline Outlook 2025: Insights Into Therapies, Research, and Market PotentialSeptember 8, 2025 | theglobeandmail.comNuveen LLC Acquires New Stake in Tyra Biosciences, Inc. $TYRASeptember 7, 2025 | marketbeat.comWe're Hopeful That Tyra Biosciences (NASDAQ:TYRA) Will Use Its Cash WiselySeptember 6, 2025 | finance.yahoo.comTyra Biosciences, Inc. $TYRA Shares Sold by Ally Bridge Group NY LLCSeptember 5, 2025 | marketbeat.comTyra Biosciences, Inc. $TYRA Shares Purchased by Vestal Point Capital LPSeptember 4, 2025 | marketbeat.comRaymond James Initiates Coverage of Tyra Biosciences (TYRA) with Strong Buy RecommendationSeptember 4, 2025 | msn.comTyra Biosciences management to meet with OppenheimerSeptember 4, 2025 | msn.comTyra Biosciences initiated with a Strong Buy at Raymond JamesSeptember 3, 2025 | msn.comWalleye Capital LLC Has $1.31 Million Stake in Tyra Biosciences, Inc. $TYRASeptember 1, 2025 | marketbeat.comAlphaQuest LLC Raises Stock Holdings in Tyra Biosciences, Inc. $TYRAAugust 31, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Earns Buy Rating from HC WainwrightAugust 24, 2025 | marketbeat.comTyra Biosciences initiates paediatric study for achondroplasia treatmentAugust 22, 2025 | finance.yahoo.comTyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric AchondroplasiaAugust 21, 2025 | prnewswire.comTyra Biosciences, Inc. (NASDAQ:TYRA) Receives Consensus Rating of "Buy" from AnalystsAugust 21, 2025 | marketbeat.comTyra Biosciences Announces Participation at Upcoming Investor EventsAugust 20, 2025 | prnewswire.comDelveInsight Business Research, LLP: FGFR Inhibitors Market Set to Surge by 2034 as Targeted Cancer Therapies Transform Treatment Paradigms | DelveInsightAugust 20, 2025 | finanznachrichten.deFGFR Inhibitors Market Set to Surge by 2034 as Targeted Cancer Therapies Transform Treatment Paradigms | DelveInsightAugust 19, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVCT, TYRA, GOSS, and PROK Company DescriptionsGossamer Bio NASDAQ:GOSS$3.46 0.00 (0.00%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.48 +0.02 (+0.46%) As of 09/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.Nuvectis Pharma NASDAQ:NVCT$6.16 -0.35 (-5.38%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$6.36 +0.20 (+3.23%) As of 09/12/2025 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.ProKidney NASDAQ:PROK$2.48 -0.50 (-16.78%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.50 +0.02 (+0.97%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.Tyra Biosciences NASDAQ:TYRA$12.52 +0.05 (+0.40%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$12.52 +0.01 (+0.04%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
